Menu
×
Don't Miss Out!
Get your weekly Breakfast Briefing eNewsletter, filled with news, trends, and vital information from DIA!
DIA 2021 Global Annual Meeting
Antibody-Drug Conjugate Drug Development: From Novel Technology to New Patient Therapy
Session Chair(s)
Angela Qu, MD, PhD
- Vice President, Translational Medicine
- Parexel, United States
In this session, the expert speakers will describe and discuss the key learnings from this cutting-edge and arguably intriguing topic and promote open thoughts on how to innovate next-generation of ADC development and identify new opportunities to broaden ADC applications to deliver new therapies to help fulfill unmet medical needs.
Learning Objective : Illustrate up-to-date ADCs drug development landscape along with therapeutic applications and opportunities; Describe scientific rationales for Antibody-Drug Conjugate (ADC) drug design and novel technological platforms; Discuss case studies of novel ADCs development from bench to clinical and from clinical to successful launch; Discuss strategic and operational considerations unique to ADC including key challenges and translational needs for ADC drugs from preclinical into clinical.
Speaker(s)
The Evolution of Antibody-Drug Conjugates in the Era of Precision Medicine Development
Angela Qu, MD, PhD
- Vice President, Translational Medicine
- Parexel, United States
Bispecific ADC Technology Platforms and M1231: A Bispecific ADC Targeting EGFR and MUC1
Joern-Peter Halle, PhD
- Senior Vice President, Global Head of Research
- Merck KGaA, Germany
Before the DREAMM: Preclinical Findings Leading to Development of Belantamab Mafodotin
Joanna B. Opalinska, MD
- Senior Director, Oncology Clinical Development
- GlaxoSmithKline, United States